Holen Sie sich die Stockscreener-App
0.6001
4.42%
0.0254
Schlusskurs vom Vortag:
$0.5747
Offen:
$0.575
24-Stunden-Volumen:
3.61M
Relative Volume:
4.18
Marktkapitalisierung:
$2.69M
Einnahmen:
$72,100
Nettoeinkommen (Verlust:
$-3.60M
KGV:
-0.5043
EPS:
-1.19
Netto-Cashflow:
$-3.37M
1W Leistung:
-3.21%
1M Leistung:
+3.41%
6M Leistung:
-69.69%
1J Leistung:
-74.89%
1-Tages-Spanne:
$0.565
$0.72
1-Wochen-Bereich:
$0.55
$0.72
52-Wochen-Spanne:
$0.4101
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Firmenname
Silo Pharma Inc
Sektor
Branche
Telefon
(718) 400-9031
Adresse
677 N. WASHINGTON BLVD, SARASOTA
Vergleichen Sie SILO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4126 | 597.27M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.25 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.08 | 128.33M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1602 | 360.17M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.18 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Aktie (SILO) Neueste Nachrichten
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 - The Manila Times
Silo Pharma completes dosing in FDA-requested safety study for PTSD drug By Investing.com - Investing.com South Africa
Major PTSD Drug Advances: FDA Safety Study Complete, Novel Nasal Delivery System Shows Promise - Stock Titan
Certain Options of Silo Pharma, Inc. are subject to a Lock-Up Agreement Ending on 16-JUL-2025. - MarketScreener
Certain Common Stock of Silo Pharma, Inc. are subject to a Lock-Up Agreement Ending on 16-JUL-2025. - MarketScreener
What makes Silo Pharma Inc. stock price move sharplySmart Money Trade Setups - Newser
Why Silo Pharma Inc. stock attracts strong analyst attentionLow Risk Trading Ideas - Newser
How Silo Pharma Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
Silo Pharma Faces Nasdaq Non-Compliance Notice - MSN
Silo Pharma (NASDAQ:SILO) Upgraded to “Sell” at Wall Street Zen - Defense World
Silo Pharma Secures Exclusive License for CNS Peptides - TipRanks
Silo Pharma expects SPC-15 PTSD drug preclinical data within 90 days - Investing.com
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 - GlobeNewswire
Silo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026 - Nasdaq
Revolutionary PTSD Treatment Breaks 25-Year Innovation Drought: Nasal Spray Shows Promise - Stock Titan
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic - MSN
Silo Pharma (NASDAQ:SILO) Trading Down 3.2% – Time to Sell? - Defense World
Silo Pharma receives Nasdaq notice for minimum bid price non-compliance - Investing.com Australia
Silo Pharma and Hoth Therapeutics plan joint venture for obesity treatment - Investing.com India
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
SILO Pharma Secures USPTO Approval for Key Patent Enhancing SPC-15 Protection | SILO Stock News - GuruFocus
Silo Pharma receives patent allowance for PTSD treatment technology - Investing.com
Silo Pharma receives patent allowance for PTSD treatment technology By Investing.com - Investing.com Canada
Silo Pharma, Inc. Receives Notice of Allowance for Patent Strengthening SPC-15 Treatment for PTSD - Nasdaq
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - GlobeNewswire
Breakthrough PTSD Drug Patent: Silo Pharma's Intranasal Treatment Advances Toward Clinical Trials - Stock Titan
Silo Pharma Stock Plunges 18.76% After Bitcoin Investment - AInvest
Silo Pharma approves purchase of Bitcoin as treasury reserve asset; shares up - MSN
Silo Pharma allocates $1 million to Bitcoin holdings By Investing.com - Investing.com South Africa
Is Silo Pharma moving to BIO Protocol? No - Binance
Silo Pharma's Board Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset; Shares Rise - MarketScreener
Silo Pharma (SILO) Allocates $1 Million for Bitcoin Investment | - GuruFocus
Silo Pharma allocates $1 million to Bitcoin holdings - Investing.com
Silo Pharma stock surges on Bitcoin reserve move - Investing.com
Silo Pharma stock surges on Bitcoin reserve move By Investing.com - Investing.com South Africa
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset - The Manila Times
Silo Pharma, Inc. Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset - Nasdaq
Biotech Makes Bold Move: Silo Pharma Commits $1M to Bitcoin as Inflation Shield - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Silo Pharma's (NASDAQ:SILO) Groundbreaking Therapies Could Change The Treatment Landscape For PTSD, Fibromyalgia, MS & Alzheimer’s - simplywall.st
Silo Pharma advances PTSD treatment with new drug-device study By Investing.com - Investing.com South Africa
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 - GlobeNewswire
Silo Pharma stock plunges to 52-week low of $0.47 By Investing.com - Investing.com Canada
Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug - Seeking Alpha
SiloPharma (SILO) Advances SPC-15 with New Drug-Device Study Agreement | SILO Stock News - GuruFocus
Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15 - marketscreener.com
Silo Pharma advances PTSD treatment with new drug-device study - Investing.com Australia
Finanzdaten der Silo Pharma Inc-Aktie (SILO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Silo Pharma Inc-Aktie (SILO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President |
Dec 13 '24 |
Buy |
0.84 |
2,500 |
2,097 |
187,932 |
| Weisblum Eric | CEO and President |
Nov 20 '24 |
Buy |
0.95 |
2,500 |
2,375 |
182,932 |
| Weisblum Eric | CEO and President |
Nov 22 '24 |
Buy |
0.90 |
2,500 |
2,250 |
185,432 |
3.40%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):